focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Well done BigBiteNow. Great notes and synopsis of yesterday’s presentation.
I sold out early yesterday, then listened to the presentation and immediately bought back on the basis of the reduced P3 trial costs and re-engagement with pharma companies and the statements regarding efficacy against MRSA and minimal risk of liver/kidney toxicity.
Be interesting to see where these trade today, given that RG and M&G are putting in £30m at 15p!
Well they have approximately one years cash flow in the bank, so the CEO had better start signing some commercial agreements pretty soon to fund the technology roadmap.
The share price has already fallen 40% from the last placing, so I doubt there will be much appetite from the market to provide further funding, let alone us poor sods who are 90% down from the IPO!
If Amati want out, why has the CEO not contacted Bracco or Nukem to purchase their holding.
Nukem increased their stake in August by 0.5% when the share price was 15p, whilst Branco invested in the last capital raise at I think 60p. For little more than £1m they could acquire a 10% stake in the company. It makes no sense to allow a continual drip feed of sales to trash the share price, unless of course they have lost complete faith in the prospects for the company.
seems strange that for a supposed revolution in lung imaging technology, the company seems completely incapable of commercialising the product.
what we don’t need is the ceo/cfo trotting through a 25 page interim results presentation leaving minimal time for questions. we all know what the company does. we require an honest assessment from the new ceo of the company’s commercial development, and more importantly how they intend to finance the company going forward. the time for bull****ting is over.